Pharmaceutical major Alembic informed the BSE that it had “successfully completed the United States Food and Drug Administration (USFDA) inspection for its Bioequivalence Facility located at Vadodara without any observations.”
The USFDA conducts such investigations of all pharmaceutical manufacturers whose products are sold in the US. The inspection helps the USFDA confirm the “bioequivalence between generic drugs and their brand-name counterparts.”
The inspection was conducted from 17th October, 2022 to 21st October, 2022.